Trials / Completed
CompletedNCT05590793
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
A Multicentre, Open-label, Single-arm Study to Investigate the Efficacy and Safety of Triptorelin Pamoate 22.5 mg 6-month Formulation in Chinese Patients With Locally Advanced or Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 195 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triptorelin pamoate (embonate) salt | Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1. |
Timeline
- Start date
- 2022-11-17
- Primary completion
- 2024-08-20
- Completion
- 2024-08-20
- First posted
- 2022-10-21
- Last updated
- 2025-09-09
- Results posted
- 2025-09-09
Locations
36 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05590793. Inclusion in this directory is not an endorsement.